Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425329 | 0.90 | TRPV1 (0.67) | TRPV1MEN1KMT2AALDH1A1NOTUM | |
| SCHEMBL4422126 | 0.89 | TRPV1 (0.54) | TRPV1MEN1KMT2AALDH1A1NOTUM | |
| SCHEMBL4427488 | 0.83 | TRPV1 (0.61) | TRPV1MEN1KMT2ANOTUMPABPC1 | |
| SCHEMBL4426043 | 0.83 | KDM4E (0.53) | TRPV1MEN1KMT2AALDH1A1NOTUM | |
| SCHEMBL13863942 | 0.81 | TRPV1 (0.47) | TRPV1MEN1KMT2ANOTUMNPC1 | |
| SCHEMBL4425260 | 0.81 | TRPV1 (0.47) | TRPV1MEN1KMT2ANOTUMNPC1 | |
| SCHEMBL1542696 | 0.80 | ALDH1A1 (0.67) | TRPV1MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL4434064 | 0.80 | CYP2C9 (0.54) | MEN1KMT2ACYP2C9 | |
| SCHEMBL4433782 | 0.80 | TRPV1 (1.00) | TRPV1MEN1KMT2AALDH1A1PABPC1 | |
| SCHEMBL18132530 | 0.78 | MEN1 (0.61) | TRPV1MEN1KMT2AALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | TRPV1 1/4885MEN1 3527/4885KMT2A 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.